Tempus AI Stock Jumps As Data Presentations Fuel Fresh AI Oncology Buzz

All NewsApril 14, 2026

Tempus AI gains as AACR 2026 abstracts highlight biomarkers and cancer subtypes, while Jefferies starts coverage with an Underperform rating.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent